- Nurix Therapeutics ( NASDAQ: NRIX ) to sell pre-funded warrants to purchase 2,869,440 shares of common stock at a price of $13.939 per pre-funded warrant for total gross proceeds of approximately $40M in a registered direct offering.
- The offering is expected to close on July 11, 2022.
- Net proceeds together with existing cash, cash equivalents and investments will be used to fund clinical trials, manufacturing and process development, research, working capital, capital expenditures and other general corporate purposes.
- The company says net proceeds from this offering, together with existing cash, cash equivalents and investments, excluding any future potential milestones from collaborations, will be sufficient to fund its operating activities into the second half of 2024.
- Shares up 3.4% PM.
For further details see:
Nurix Therapeutics to raise $40M via registered direct offering